logo
logo
PRAX stock ticker logo

Praxis Precision Medicines, Inc.

NASDAQ•PRAX
CEO: Mr. Marcio Silva De'Souza M.B.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-10-16
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
連絡先情報
99 High Street, 30th Floor, Boston, MA, 02110, United States
617-300-8460
praxismedicines.com
時価総額
$6.41B
PER (TTM)
-22.5
17.5
配当利回り
--
52週高値
$356.00
52週安値
$26.70
52週レンジ
84%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$3.52+0.00%
直近4四半期の推移

フリーCF

-$77.26M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Clinical Milestones Achieved Positive topline results announced for ulixacaltamide Phase 3 Essential3 ET program in Q4 2025; NDA submitted.
Relutrigine NDA Submission EMBOLD study showed positive results for relutrigine in DEEs; NDA submitted, commercial prep underway.
Strong Cash Position Cash, equivalents, and securities totaled $926.1M as of December 31, 2025, funding operations into 2028.
Vormatrigine Phase 2 Success RADIANT Phase 2 study showed positive PK, safety, and efficacy results for vormatrigine in H2 2025.

リスク要因

Increased Operating Losses Net loss widened to $(303.3M) in 2025 from $(182.8M) in 2024; incurred $249.1M cash burn.
High R&D Expense Growth R&D expenses increased $114.7M to $267.1M in 2025, driven by clinical trial acceleration across platforms.
Need for Future Capital Expect substantial operating expenses to continue; may need additional capital sooner than anticipated.
Regulatory Approval Uncertainty Development subject to lengthy, unpredictable FDA processes; approval for candidates not guaranteed despite positive data.

見通し

Elsunersen Data Expected Expect topline results for elsunersen EMBRAVE Part A study in H1 2026; EMBRAVE3 Phase 3 results expected 2027.
Vormatrigine Registrational Trials POWER1 topline results expected Q2 2026; POWER2 completion expected H2 2026; plan NDA submission in 2027.
Pipeline Advancement Focus Anticipate nominating development candidates for PRAX-080, PRAX-090, and PRAX-100 in H1 2026.
Commercialization Preparation Plan to expand workforce, focusing on building sales, marketing, and distribution infrastructure for potential launches.

同業比較

売上高 (TTM)

ACAD stock ticker logoACAD
$1.07B
+11.9%
LGND stock ticker logoLGND
$268.09M
+60.4%
SLNO stock ticker logoSLNO
$190.41M
+0.0%

粗利益率 (最新四半期)

PRME stock ticker logoPRME
4698.2%
-3591.0pp
KYMR stock ticker logoKYMR
2763.6%
-2680.7pp
LGND stock ticker logoLGND
143.6%
+2.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PRAX$6.41B-22.5-58.7%0.0%
KYMR$6.33B-21.0-29.1%4.7%
IMVT$5.09B-9.8-65.8%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月30日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし